Toxicity and Clinical Trial of Azaserine and 6-Thioguanine in Advanced Solid Malignant Neoplasms
1964

Clinical Trial of Azaserine and 6-Thioguanine for Cancer Treatment

Sample size: 26 publication Evidence: low

Author Information

Author(s): J. M. Schroeder, F. J. Ansfield, A. R. Curreri, G. A. LePage

Primary Institution: Cancer Research Hospital, Madison, Wisconsin

Hypothesis

The combination of azaserine and 6-thioguanine will be more effective in treating advanced solid malignant neoplasms than either drug alone.

Conclusion

The combination of azaserine and 6-thioguanine showed some effectiveness in treating certain types of cancer, particularly breast cancer, but also resulted in significant toxicity.

Supporting Evidence

  • Four out of seven women treated for breast cancer showed improvement.
  • One patient with squamous cell carcinoma of the lip also showed improvement.
  • Three out of six patients treated for more than three courses developed thrombocytopenia.

Takeaway

Doctors tested two cancer drugs together to see if they work better than alone, and they found some patients got better, but the drugs also made some people very sick.

Methodology

The trial included a toxicity phase (Phase I) to determine the maximum tolerated dose and a clinical evaluation phase (Phase II) to assess therapeutic effects in patients with malignant neoplastic disease.

Potential Biases

The study may have selection bias as patients were already known to have malignant neoplastic disease and had received prior therapies.

Limitations

The study had a small sample size and the results may not be generalizable.

Participant Demographics

The study included 10 patients in Phase I and 16 patients in Phase II, with a mix of ages and both genders.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication